Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Mufti

Showing results (181-190 of 202) with videos related to

Pageof 21
Sort By:
Leukemia|October 1, 2011
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomideA A N Giagounidis, A Kulasekararaj, U Germing, et al.
Bone Marrow Transplantation|August 21, 2007
Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survivalZ Y Lim, W Ingram, R Brand, et al.
British Journal of Haematology|January 31, 1998
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemiaJ E Parker, A Pagliuca, A Mijovic, et al.
Alimentary Pharmacology & Therapeutics|March 25, 2010
The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosisD W Orr, R K Patel, N C Lea, et al.
Leukemia|May 7, 2015
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)A M Mohamedali, J Gäken, M Ahmed, et al.
Cancer Genetics and Cytogenetics|July 15, 1989
Clinical-cytogenetic correlations in myelodysplasia (preleukemia)R V Pierre, D Catovsky, G J Mufti, et al.
Leukemia|August 26, 2006
The JAK2 V617F mutation is rare in RARS but common in RARS-TM M Ceesay, N C Lea, W Ingram, et al.
Bone Marrow Transplantation|May 4, 2006
Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005R F Duarte, D Pamphilon, J Cornish, et al.
Leukemia Research|June 28, 2011
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosisW Nagi, Z Y Lim, P Krishnamurthy, et al.
Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.
Pageof 21

Showing results (181-190 of 202) with videos related to

Sort By:
Pageof 21
Leukemia|October 1, 2011
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomideA A N Giagounidis, A Kulasekararaj, U Germing, et al.
Bone Marrow Transplantation|August 21, 2007
Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survivalZ Y Lim, W Ingram, R Brand, et al.
British Journal of Haematology|January 31, 1998
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemiaJ E Parker, A Pagliuca, A Mijovic, et al.
Alimentary Pharmacology & Therapeutics|March 25, 2010
The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosisD W Orr, R K Patel, N C Lea, et al.
Leukemia|May 7, 2015
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)A M Mohamedali, J Gäken, M Ahmed, et al.
Cancer Genetics and Cytogenetics|July 15, 1989
Clinical-cytogenetic correlations in myelodysplasia (preleukemia)R V Pierre, D Catovsky, G J Mufti, et al.
Leukemia|August 26, 2006
The JAK2 V617F mutation is rare in RARS but common in RARS-TM M Ceesay, N C Lea, W Ingram, et al.
Bone Marrow Transplantation|May 4, 2006
Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005R F Duarte, D Pamphilon, J Cornish, et al.
Leukemia Research|June 28, 2011
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosisW Nagi, Z Y Lim, P Krishnamurthy, et al.
Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.
Pageof 21